US FDA warns high-dose Diflucan linked to birth defects
This article was originally published in Scrip
Executive Summary
Based on several published case reports, the US FDA on 3 August warned that chronic, high doses of 400-800mg/day of Pfizer's Diflucan (fluconazole) may be associated with a rare and distinct set of congenital anomalies in infants whose mothers were treated with the drug for serious and life-threatening fungal infections during the first trimester of pregnancy.